Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

3 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.

Munching on nuts may be protective against oesophageal cancer

10 Aug 2018

Consumption of nuts appears to lead to a reduced risk of oesophageal squamous cell carcinoma (ESCC) in a high-risk population, according to data from the Golestan Cohort Study.

The study included 48,284 participants (mean age 52.1 years; 42.3 percent male; 70.2 percent had no formal education) in Northeastern Iran. Among nut consumers, 11,554 consumed a median of 0.2 g per 1,000 kcal/day (tertile 1), 11,540 a median of 0.9 g per 1,000 kcal/day and 11,857 a median of 2.8 g per 1,000 kcal/day.

There were 280 participants who developed ESCC during a median follow-up of 9 years. Compared with nonconsumers (n=13,333), individuals in the highest tertile of total nut consumption had a lower risk of incident ESCC (adjusted hazard ratio [HR], 0.60; 95 percent CI, 0.39–0.93; p=0.02).

When the effect of each type of nut was examined, a similar risk reduction was observed for the highest tertile of mixed nut and seed intake (adjusted HR, 0.52; 0.32–0.84; p=0.002). In contrast, neither peanut nor walnut was associated with ESCC.

Each 5-g of total nuts consumed per day yielded a statistically significant 29-percent decrease in ESCC risk. On further analysis among nut consumers, the risk decrease was greater for the highest vs the lowest quartile of nut consumption (adjusted HR, 0.59; 0.35–0.99).

Researchers explained that the lack of a significant effect for peanut or walnut consumption could be due to lower intake of peanuts and walnuts relative to mixed nuts and seeds in the present population. It could also be attributed to the different compositions of different types of nuts, as the vitamin, mineral and fatty acid composition differ among types.

Specifically, among nuts and seeds, watermelon and pumpkin seeds are the best source of zinc, which is about three times more than in peanuts or walnuts. Zinc has been reported to be inversely associated with the risk of ESCC. [Am J Clin Nutr 2015;102;102-108; Middle East J Dig Dis 2014;6:177-185]

Additional investigations are required to confirm the present data and to clarify the effect of nut consumption on the risk of total mortality, specific causes of mortality and incidence of other cancers, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

3 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.